Retatrutide vs Ozempic: Three Receptors Against One
Comparing retatrutide with Ozempic is comparing two things that are not in the same category. Ozempic is an approved medicine with a manufacturer, a label, a prescriber and a supply chain. Retatrutide is an investigational compound in phase 3 trials that reaches people through a research chemical market. Any comparison that only puts weight loss percentages side by side is leaving out the part that actually decides the choice.
This page does both halves. The pharmacology first, because the receptor difference is real and interesting, then the practical comparison including everything the trial data does not cover.
The Receptor Difference
Semaglutide, the compound sold as Ozempic and Wegovy, is a single agonist. It activates the GLP-1 receptor, which slows gastric emptying, increases satiety signalling in the hypothalamus and improves glucose dependent insulin secretion. That single mechanism is responsible for essentially everything semaglutide does.
Retatrutide is a triple agonist. It hits GLP-1, GIP and the glucagon receptor. The first two are shared with tirzepatide. The glucagon receptor is what makes retatrutide structurally different from everything currently approved.
| Receptor | What activating it does | Semaglutide | Retatrutide |
|---|---|---|---|
| GLP-1 | Satiety, slowed gastric emptying, glucose dependent insulin release | Yes | Yes |
| GIP | Insulin sensitisation, and appears to blunt GLP-1 nausea | No | Yes |
| Glucagon | Raises energy expenditure and mobilises hepatic fat | No | Yes |
The glucagon arm is the part worth understanding, because it is counterintuitive. Glucagon is the hormone that raises blood sugar, which sounds like the opposite of what a diabetes drug should do. What it also does is increase resting energy expenditure and drive hepatic fat mobilisation, and in the context of simultaneous GLP-1 agonism the glucose raising effect is offset. The net result is a compound that reduces intake like a GLP-1 drug and additionally raises output, which no approved agent does.
That is the mechanistic argument for why retatrutide produces larger weight loss figures than semaglutide. It is not simply a stronger version of the same thing. It is doing something extra.
What the Trial Data Showed
The comparison people want is a head to head trial, and it does not exist. What exists is separate programmes with different populations, durations and endpoints, which means any comparison is indirect and should be read with that caveat attached.
Semaglutide at 2.4mg weekly, in the obesity programme, produced mean weight loss in the region of 15 percent over 68 weeks. Retatrutide, in its phase 2 obesity study, reported mean weight loss around 24 percent at 48 weeks at the highest dose, with the curve still descending at the end of the study rather than plateauing.
Two things about that comparison are worth being careful about. The retatrutide figure comes from phase 2, which is smaller and less definitive than the phase 3 programme semaglutide has completed. And the still descending curve is genuinely notable, because it suggests the study ended before the effect did, but it is also the kind of finding that regresses in larger trials more often than not. The retatrutide guide covers the trial design in more detail.
Side Effects
Both compounds produce gastrointestinal effects and both do so in a dose dependent way. Nausea, vomiting, diarrhoea and constipation dominate the adverse event tables for the entire drug class, and titration exists specifically to manage them.
Where the two differ is what the additional receptors contribute. GIP agonism appears to blunt GLP-1 mediated nausea, which is part of why tirzepatide is often described as better tolerated than semaglutide at equivalent efficacy. Retatrutide has that same GIP arm. Against it, the glucagon arm brings its own effects, with increased heart rate the one that gets the most attention in the trial data.
The practical reading is that retatrutide is not obviously worse tolerated than semaglutide despite producing more weight loss, which is unusual, and that the cardiovascular signal is the thing phase 3 is there to characterise properly. The semaglutide side effects page covers the approved compound in detail.
The Comparison That Actually Decides It
Everything above is pharmacology. The decision is usually made on the four rows below, which have nothing to do with receptors.
| Ozempic / Wegovy | Retatrutide | |
|---|---|---|
| Regulatory status | FDA approved, prescribable | Investigational, phase 3, no approval anywhere |
| How you get it | Prescription, pharmacy dispensed | Research chemical vendors only |
| Quality assurance | Pharmaceutical manufacture, batch release, recall mechanism | Voluntary vendor testing, no oversight |
| Cost per month | $400 to $1,300 depending on route and coverage | $30 to $365 depending on dose |
| Dosing guidance | Approved label with a validated titration schedule | Extrapolated from phase 2 protocols |
Read honestly, retatrutide wins on efficacy data and cost, and loses on every column concerning whether the vial contains what the label says and whether anyone is accountable if it does not. Which set matters more is a judgement about risk tolerance rather than a question with a pharmacological answer, and anyone presenting it as obvious in either direction is selling something.
Comparing the research market listings
Apollo catalogues all three GLP compounds under coded names, which makes a per milligram comparison straightforward. Vendors scored in the 2026 scorecard.
Retatrutide, GLP-3 R Semaglutide, GLP-1 SWhere Tirzepatide Sits Between Them
Tirzepatide is the compound most people should be comparing against, and it usually gets skipped because Ozempic is the name everyone knows. It is dual agonist, GLP-1 and GIP, which puts it mechanistically between semaglutide and retatrutide. It is approved, so it has the regulatory column that retatrutide lacks. And its obesity programme produced mean weight loss in the region of 20 percent, closer to retatrutide than to semaglutide.
For someone weighing efficacy against having an actual supply chain, tirzepatide is the compound that makes the trade least painful, which is why the tirzepatide versus retatrutide comparison is the more useful page for most people than this one. The semaglutide versus tirzepatide page covers the two approved options against each other. Apollo lists it as GLP-2 T in the research market.
Practical Differences If You Are Actually Running One
- Dose scale. Semaglutide runs 0.25mg to 2.4mg weekly. Retatrutide runs in low single digit milligrams up to around 12mg. The concentrations that make sense on a syringe are therefore completely different, which the retatrutide calculator handles.
- Titration pacing. Semaglutide has an approved schedule with four week steps. Retatrutide has no label, so escalation schedules are extrapolated from the phase 2 protocol.
- Presentation. Approved semaglutide arrives as a pre-filled pen with the dose already set. Research retatrutide arrives as lyophilised powder that has to be reconstituted correctly, which the reconstitution guide covers.
- Verification. A pharmacy pen is what the label says. A research vial is what a certificate says, if there is one, which is why the testing guide exists.
If the question is which compound suits a goal rather than which is stronger, the stack builder works through it properly, and the weight loss overview covers the whole class rather than these two.
Key Takeaways
- Semaglutide is a single GLP-1 agonist; retatrutide adds GIP and glucagon, and the glucagon arm is what nothing approved currently does
- Glucagon agonism raises energy expenditure and mobilises hepatic fat, which is why retatrutide is not just a stronger GLP-1 drug
- No head to head trial exists, so the 15 percent versus 24 percent comparison is indirect and comes from different phases
- The retatrutide weight loss curve had not plateaued at 48 weeks, which is notable and not yet confirmed at scale
- GIP agonism appears to blunt nausea, so retatrutide is not obviously worse tolerated despite doing more
- Semaglutide wins on approval, manufacture and accountability; retatrutide wins on data and cost
- Tirzepatide sits between them and is the comparison most people should actually be making
Frequently Asked Questions
Is retatrutide stronger than Ozempic?
On the available trial data, yes, though the comparison is indirect because no head to head study has been run. Semaglutide at 2.4mg produced mean weight loss around 15 percent over 68 weeks in its obesity programme; retatrutide reported around 24 percent at 48 weeks in phase 2. The retatrutide figure comes from a smaller and earlier stage trial, so it carries more uncertainty than the semaglutide number does.
What is the difference between retatrutide and semaglutide?
Receptor coverage. Semaglutide activates the GLP-1 receptor only, which drives satiety and slowed gastric emptying. Retatrutide activates GLP-1, GIP and glucagon receptors. The glucagon arm is the structural difference: it raises resting energy expenditure and mobilises liver fat, so retatrutide reduces intake like a GLP-1 drug and additionally increases output, which nothing approved currently does.
Why does retatrutide activate the glucagon receptor?
Because glucagon does more than raise blood sugar. It increases resting energy expenditure and drives hepatic fat mobilisation, and when it is activated alongside GLP-1 agonism the glucose raising effect is offset by the insulin side. The combination gives an agent that works on both sides of the energy balance equation rather than only on intake, which is the design rationale for the whole triple agonist class.
Is retatrutide FDA approved?
No. It is an investigational compound in phase 3 trials with no approval in any jurisdiction, no prescribing information and no pharmacy route. It also cannot be legally compounded, because compounding pharmacies may only work from approved active ingredients or ones on an official shortage list. Every vial available to buy is research grade material sold for laboratory use.
Which has worse side effects, retatrutide or Ozempic?
Both produce dose dependent gastrointestinal effects and those dominate the adverse event tables for the entire class. Retatrutide includes GIP agonism, which appears to blunt GLP-1 mediated nausea, so it is not obviously worse tolerated despite producing more weight loss. Against that, the glucagon arm brings increased heart rate, which is the signal phase 3 is designed to characterise. Neither has a clean tolerability advantage.
Should I choose tirzepatide instead?
For many people, yes. Tirzepatide is dual agonist, GLP-1 and GIP, which puts it mechanistically between semaglutide and retatrutide, and its obesity programme produced mean weight loss around 20 percent, closer to retatrutide than to semaglutide. Crucially it is approved, so it comes with pharmaceutical manufacture and a prescriber. It is the option that makes the trade between efficacy and accountability least painful.